UNSPSC 51323005: Levocarnitine hydrochloride

This classification denotes a nutritional supplement with the molecular formula C7H15NO3.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J3Y5E6IKS3. European Medicines Agency schedules levocarnitine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02906MIG. The term levocarnitine hydrochloride is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule levocarnitine hydrochloride under HS 29239000 and SITC 51481.

As of Q4 2014, LEVOCARNITINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C[N+](C)(C)C[C@@H](CC(=O)O)O.[CL-].

UNSPSC 51323005 Levocarnitine hydrochloride is a Commodity code covering individual pharmaceutical products for clinical and emergency medical use. State and local governments procure this and related medications for fire rescue services, public health programs, and multistate cooperative purchasing consortiums that serve health facilities across participating jurisdictions. Recent solicitations show procurement of advanced life support medications for emergency response, generic pharmaceuticals for distributed health-system use, and direct-to-manufacturer pharmacy programs at the state health-benefits level. Issuing bodies include municipal fire departments, state health and human services agencies, and cooperative purchasing alliances that aggregate demand across multiple states and local entities. The City of Tampa's Purchasing Department, Minnesota's Department of Administration (administering MMCAP), and the Texas Health and Human Services Commission appear in recent activity; these represent the range from individual city procurement to multistate cooperative vehicles.

Geographic activity centers on Texas, Minnesota (and participating states including Oregon), and Florida, with procurement spanning emergency medical supplies for municipal fire rescue, state-administered health-benefits pharmacy programs, and cooperative purchasing for hospital and clinic networks. The City of Tampa issued an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications including epinephrine, adenosine, labetalol, and diltiazem for Tampa Fire Rescue, with an estimated contract value of $40,000.00 and a response deadline of April 8, 2026; the notice included a 5 percent bid discount for Small Local Business Enterprise participation and required OSHA-compliant Safety Data Sheets. The Minnesota Department of Administration issued an RFP (S1070000015802) through MMCAP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026, requiring vendors to supply through three authorized wholesalers and meet cGMP and DSCSA compliance. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026, to gather information on direct-to-manufacturer prescription programs without a formal award timeline or budget allocation at that preliminary stage.